Graig Suvannavejh
Stock Analyst at Mizuho
(4.53)
# 266
Out of 5,152 analysts
174
Total ratings
54.55%
Success rate
21.59%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $135.49 | +84.52% | 2 | Feb 25, 2026 | |
| INSM Insmed | Maintains: Outperform | $211 → $204 | $149.88 | +36.11% | 13 | Feb 24, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $5.98 | +67.22% | 1 | Feb 19, 2026 | |
| IMMX Immix Biopharma | Initiates: Outperform | $14 | $8.56 | +63.55% | 1 | Feb 9, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $15.12 | -66.93% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $42.53 | +26.97% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $177.79 | +9.12% | 2 | Dec 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $28.54 | +61.18% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $76.20 | +31.23% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $10.18 | +125.93% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $70.02 | -20.02% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $34.68 | +32.64% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $164.08 | +23.11% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $19 | $19.86 | -4.33% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.65 | +142.42% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.35 | +8,588.10% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $2.15 | +62.79% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.05 | +63.93% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.17 | +93.42% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $17.84 | -38.34% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $18.00 | +44.44% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $15.05 | -46.84% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $33.73 | -2.16% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.63 | +366.26% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $8.42 | +778.86% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.81 | -64.41% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $91.00 | -61.54% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $26.84 | -70.19% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $62.27 | -8.46% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $29.19 | -82.87% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $10.97 | +209.94% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $10.37 | +170.01% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $28.88 | +7.34% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $15.05 | +2,424.92% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.63 | +191.41% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $24.12 | +49.25% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $33.69 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $2.81 | +1,216.73% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $188.69 | -32.16% | 1 | Sep 14, 2020 |
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $135.49
Upside: +84.52%
Insmed
Feb 24, 2026
Maintains: Outperform
Price Target: $211 → $204
Current: $149.88
Upside: +36.11%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $5.98
Upside: +67.22%
Immix Biopharma
Feb 9, 2026
Initiates: Outperform
Price Target: $14
Current: $8.56
Upside: +63.55%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $15.12
Upside: -66.93%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $42.53
Upside: +26.97%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $177.79
Upside: +9.12%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $28.54
Upside: +61.18%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $76.20
Upside: +31.23%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $10.18
Upside: +125.93%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $70.02
Upside: -20.02%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $34.68
Upside: +32.64%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $164.08
Upside: +23.11%
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $19.86
Upside: -4.33%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.65
Upside: +142.42%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.35
Upside: +8,588.10%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.15
Upside: +62.79%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.05
Upside: +63.93%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.17
Upside: +93.42%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $17.84
Upside: -38.34%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $18.00
Upside: +44.44%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $15.05
Upside: -46.84%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $33.73
Upside: -2.16%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.63
Upside: +366.26%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $8.42
Upside: +778.86%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.81
Upside: -64.41%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $91.00
Upside: -61.54%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $26.84
Upside: -70.19%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $62.27
Upside: -8.46%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $29.19
Upside: -82.87%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $10.97
Upside: +209.94%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $10.37
Upside: +170.01%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $28.88
Upside: +7.34%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $15.05
Upside: +2,424.92%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.63
Upside: +191.41%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $24.12
Upside: +49.25%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $33.69
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $2.81
Upside: +1,216.73%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $188.69
Upside: -32.16%